Preston Klassen
2012 - Orexigen Therapeutics
In 2012, Preston Klassen earned a total compensation of $1.3M as Head of Global Contrave Program and Executive Vice President, Product Development at Orexigen Therapeutics, a 41% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $240,500 |
|---|---|
| Option Awards | $655,795 |
| Salary | $370,000 |
| Other | $120 |
| Total | $1,266,415 |
Klassen received $655.8K in option awards, accounting for 52% of the total pay in 2012.
Klassen also received $240.5K in non-equity incentive plan, $370K in salary and $120 in other compensation.
Rankings
In 2012, Preston Klassen's compensation ranked 5,206th out of 11,487 executives tracked by ExecPay. In other words, Klassen earned more than 54.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,206 out of 11,487 | 55th |
Division Manufacturing | 1,819 out of 4,253 | 57th |
Major group Chemicals And Allied Products | 436 out of 1,203 | 64th |
Industry group Drugs | 285 out of 925 | 69th |
Industry Pharmaceutical Preparations | 224 out of 700 | 68th |
Source: SEC filing on April 22, 2015.
Klassen's colleagues
We found four more compensation records of executives who worked with Preston Klassen at Orexigen Therapeutics in 2012.